A Dark Vector Cognition product

Moderna 8-K 2026-11-09

MRNA · CIK 1682852 · Form 8-K · Period ended November 9, 2026 · Filed November 16, 2026

1 sections, 7K characters. Original on sec.gov · ·

The 10 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2026

MODERNA, INC.

(Exact name of registrant as specified in its charter)

Delaware001-3875381-3467528
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
325 Binney Street
Cambridge, MA02142
(Address of principal executive offices)(Zip code)

Registrant’s telephone number, including area code: (617) 714-6500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareMRNAThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On November 9, 2026, Moderna, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to its Credit and Guaranty Agreement, dated as of November 19, 2025 (the “Credit Agreement”), among the Company, as borrower, the guarantor subsidiaries from time to time party thereto, the lenders from time to time party thereto and Ares Capital Corporation, as administrative agent and collateral agent. The Amendment was entered into by the Company, Ares Capital Corporation and the lenders party thereto and became effective on November 9, 2026.

The Amendment reduces the applicable interest rate margins for the initial term loans and delayed draw term loans by 0.75 percentage points, from 5.50% to 4.75% per annum for loans bearing interest at a forward-looking term rate derived from the Secured Overnight Funding Rate and from 4.50% to 3.75% per annum for loans bearing interest based on the base rate. The Amendment also extends the maturity date for those loans from November 24, 2030 to November 24, 2031.

The Amendment extends the availability period for the first $400 million of delayed draw term loan commitments from November 24, 2027 to November 24, 2029 and for the remaining $500 million of delayed draw term loan commitments from November 24, 2028 to November 24, 2029, in each case, subject to earlier termination in accordance with the Credit Agreement. Borrowings of delayed draw term loans remain subject to the applicable conditions under the Credit Agreement. Except as modified by the Amendment, the Credit Agreement remains in effect, including its guarantees and collateral security.

The above summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 2.03.Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosure set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated into this Item 2.03 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No.Description
10.1Amendment No. 1 to Credit and Guaranty Agreement, dated as of November 9, 2026, by and among Moderna, Inc., Ares Capital Corporation and the lenders party thereto.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 16, 2026MODERNA, INC.
By:/s/ James M. Mock
James M. Mock
Chief Financial Officer